Do you have a patient with thalassemia or sickle cell disease (SCD)?
The primary purpose of the Gladiolus Study is to evaluate the safety and efficacy of an investigational medication in people 12 to 65 years of age with thalassemia or SCD, as measured by improvement in anemia (Hb) and reduction in red blood cell (RBC) transfusions.
This is a Phase 2, open-label study in which up to 60 participants will be enrolled to receive 400 mg of etavopivat, which is taken as 2 tablets once a day. The total duration of the study for each participant is up to 58 weeks. This includes screening (up to 6 weeks), open-label study treatment (up to 48 weeks), and an end-of-study visit 4 weeks after the last dose of the investigational medication.